검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | 5-FU/LV |
Overview Company | Hoffmann-La Roche |
Overview Modality | ANTIBODY |
Overview Target | Colorectal Cancer |
Overview Indication | Colorectal Cancer |
Overview Phase | PHASE_2 |
Overview Status | ACTIVE |
MoA Biomarker | biomarker for systemic treatment in patients with metastatic colorectal cancer |
PK/PD Species | Mouse, Grade 3/4 toxicity occurred in 59%, with neutropenia, leukopenia, and diarrhea being the most common. |
PK/PD Animal (cat.) | Mouse |
PK/PD Experiment | pharmacokinetic |
Toxicology Species | Mouse, Grade 3/4 toxicity occurred in 59%, with neutropenia, leukopenia, and diarrhea being the most common. |
Toxicology Animal (cat.) | Mouse |
Toxicology Major finding | thrombocytopenia, and two (4%) hand-foot syndrome |
Toxicology CRS | Reported |
Clinical Primary efficacy | ORR 80.4% |
Clinical ORR | 80.4% |
Clinical PFS | 46.4 |
Clinical OS | 46.4 |
Clinical Result source | ClinicalTrials.gov NCT02337946 |
Clinical Data Tier / Score | A · 68 |
Clinical Program phase | PHASE_2 |
Clinical Clinical sync | 2026년 7월 8일 (6일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | 5-FU/LV |
Overview Company | Hoffmann-La Roche |
Overview Modality | ANTIBODY |
Overview Target | Colorectal Cancer |
Overview Indication | Colorectal Cancer |
Overview Phase | PHASE_2 |
Overview Status | ACTIVE |
MoA Biomarker | biomarker for systemic treatment in patients with metastatic colorectal cancer |
PK/PD Species | Mouse, Grade 3/4 toxicity occurred in 59%, with neutropenia, leukopenia, and diarrhea being the most common. |
PK/PD Animal (cat.) | Mouse |
PK/PD Experiment | pharmacokinetic |
Toxicology Species | Mouse, Grade 3/4 toxicity occurred in 59%, with neutropenia, leukopenia, and diarrhea being the most common. |
Toxicology Animal (cat.) | Mouse |
Toxicology Major finding | thrombocytopenia, and two (4%) hand-foot syndrome |
Toxicology CRS | Reported |
Clinical Primary efficacy | ORR 80.4% |
Clinical ORR | 80.4% |
Clinical PFS | 46.4 |
Clinical OS | 46.4 |
Clinical Result source | ClinicalTrials.gov NCT02337946 |
Clinical Data Tier / Score | A · 68 |
Clinical Program phase | PHASE_2 |
Clinical Clinical sync | 2026년 7월 8일 (6일 전) |
추천 비교
추천 비교